Risks, Benefits, and Therapeutic Potential of Hematopoietic Stem Cell Transplantation for Autoimmune Diabetes
- 509 Downloads
Type 1 diabetes mellitus is a chronic disease that results from the autoimmune response against pancreatic insulin producing β cells. Apart of several insulin regimens, since the decade of 80s various immunomodulatory regimens were tested aiming at blocking some steps of the autoimmune process against β cell mass and at promoting β cell preservation. In the last years, some independent research groups tried to cure type 1 diabetes with an “immunologic reset” provided by autologous hematopoietic stem cell transplantation in newly diagnosed patients, and the majority of patients became free form insulin with increasing levels of C-peptide along the time. In this review, we discuss the biology of hematopoietic stem cells and the possible advantages and disadvantages related to the high dose immunosuppression followed by autologous hematopoietic stem cell transplantation.
KeywordsType 1 diabetes Stem cell Hematopoietic Cure Diabetes Immunosuppression Autologous transplantation Autoimmune diabetes
No potential conflicts of interest relevant to this article were reported.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. Ann Intern Med. 1998;128:517–23.Google Scholar
- 5.Lee S, Krause DS. Adult Stem Cell Plasticity. In: Burt RK, Marmont A, editors. Stem cell therapy for autoimmune disease, Chapter 11. Austin: Landes Biosciences; 2004. p. 59–76.Google Scholar
- 28.Nelson JL, Torrez R, Louie FM, Choe OS, Storb R, Sullivan KM. Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation. J Rheumatol. 1997;24(Suppl):S23–9.Google Scholar
- 35.de Oliveira GL, Malmegrim KC, Ferreira AF, Tognon R, Kashima S, Couri CE, et al. Up-regulation of fas and fasL pro-apoptotic genes expression in type 1 diabetes patients after autologous haematopoietic stem cell transplantation. Clin Exp Immunol. 2012;168:291–302.Google Scholar
- 37.Yelin EH. The economic and functional impact of rheumatic disease in the US. In: Klippel JH, Dieppe PA. editors. Rheumatology. London: Mosby International. 1998. p. 1.5.1–1.5.4.Google Scholar
- 41.•• Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007;297:1568–76. This is the first article analyzing the safety and efficacy of autologous stem cell transplantation in humans with type 1 diabetes mellitus.Google Scholar
- 42.•• Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009;301:1573–9. This article is an update of the results previously published by Dr. Voltarelli`s group in Brazil with more patients included for a longer follow-up.Google Scholar
- 43.• Li L, Shen S, Ouyang J, Hu Y, Hu L, Cui W, et al. Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves β-cell function in Chinese patients with new onset of type 1 diabetes. J Clin Endocrinol Metab. 2012;97:1729–36. This trial shows that a small number of patients who presented diabetic ketoacidosis at the time of diagnosis may stay free from insulin for some periods.Google Scholar
- 44.• Snarski E, Milczarczyk A, Torosian T, Paluszewska M, Urbanowska E, Król M, et al. Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I. Bone Marrow Transplant. 2011;46:562–6. This article reproduces great part of the results published by Voltarelli et al.Google Scholar
- 50.Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments tregs yet transiently impairs β-cell function. Diabetes. 2012. doi: 10.2337/db12-0049.
- 53.Tauchmanovà L, Selleri C, Rosa GD, Pagano L, Orio F, Lombardi G, et al. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer. 2002;95:1076–84.Google Scholar
- 54.Tauchmanovà L, Selleri C, De Rosa G, Esposito M, Orio F Jr, Palomba S, et al. Gonadal status in reproductive age women after hematopoietic stem cell transplantation for hematological malignancies. Hum Reprod. 2003;18:1410–6.Google Scholar
- 55.• Leal AM, Oliveira MC, Couri CE, Moraes DA, Stracieri AB, Pieroni F, et al. Testicular function in patients with type 1 diabetes treated with high-dose CY and autologous hematopoietic SCT. Bone Marrow Transplant. 2012;47:467–8. This paper makes an update on side effects of autologous hematopoietic stem cell transplantation in gonadal function of patients included in Brazilian trial.PubMedCrossRefGoogle Scholar
- 58.A Trial of High Dose Immunosuppression and Autologous Hematopoietic Stem Cell Support Versus Intensive Insulin Therapy in Adults With Early Onset Type I Diabetes Mellitus. Available at: http://www.clinicaltrials.gov. Accessed 15 June 2012.